DexCom, Inc. (NASDAQ:DXCM) EVP Jacob Steven Leach sold 5,099 shares of the company’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $145.32, for a total value of $740,986.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of DXCM stock traded up $1.72 on Friday, reaching $148.04. 1,192,029 shares of the stock were exchanged, compared to its average volume of 1,336,322. The company has a current ratio of 7.18, a quick ratio of 6.75 and a debt-to-equity ratio of 1.57. The company has a market cap of $13.32 billion, a P/E ratio of 493.47 and a beta of 0.70. DexCom, Inc. has a twelve month low of $90.61 and a twelve month high of $156.16.
DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.12. DexCom had a negative net margin of 11.51% and a positive return on equity of 8.45%. The company had revenue of $280.50 million during the quarter, compared to the consensus estimate of $246.10 million. During the same quarter in the prior year, the firm posted ($0.30) earnings per share. DexCom’s revenue for the quarter was up 52.1% on a year-over-year basis. On average, equities analysts forecast that DexCom, Inc. will post 0.81 EPS for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DXCM. Vanguard Group Inc boosted its stake in DexCom by 11.5% in the third quarter. Vanguard Group Inc now owns 7,942,861 shares of the medical device company’s stock valued at $1,136,147,000 after acquiring an additional 816,247 shares in the last quarter. Arizona State Retirement System acquired a new position in DexCom in the fourth quarter valued at $942,000. Advisors Asset Management Inc. boosted its stake in DexCom by 751.6% in the fourth quarter. Advisors Asset Management Inc. now owns 5,757 shares of the medical device company’s stock valued at $690,000 after acquiring an additional 5,081 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in DexCom by 34.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 5,783 shares of the medical device company’s stock valued at $693,000 after acquiring an additional 1,471 shares in the last quarter. Finally, LS Investment Advisors LLC acquired a new position in DexCom in the fourth quarter valued at $67,000. Institutional investors own 96.50% of the company’s stock.
A number of analysts have recently weighed in on DXCM shares. Morgan Stanley upped their price objective on DexCom from $135.00 to $160.00 and gave the stock an “equal weight” rating in a research report on Monday, February 25th. UBS Group cut their price objective on DexCom from $150.00 to $140.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 30th. Cowen boosted their target price on shares of DexCom from $150.00 to $175.00 and gave the stock an “outperform” rating in a research note on Friday, February 22nd. Northland Securities reiterated a “hold” rating and set a $125.00 target price on shares of DexCom in a research note on Thursday, June 6th. Finally, Canaccord Genuity boosted their target price on shares of DexCom from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Friday, February 22nd. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $150.65.
COPYRIGHT VIOLATION WARNING: This story was published by Zolmax and is the sole property of of Zolmax. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://zolmax.com/investing/jacob-steven-leach-sells-5099-shares-of-dexcom-inc-nasdaqdxcm-stock/3114500.html.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Read More: What is meant by a buy rating?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.